David A. Margolis

6.3k total citations
50 papers, 1.8k citations indexed

About

David A. Margolis is a scholar working on Hematology, Infectious Diseases and Virology. According to data from OpenAlex, David A. Margolis has authored 50 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 19 papers in Infectious Diseases and 13 papers in Virology. Recurrent topics in David A. Margolis's work include Hematopoietic Stem Cell Transplantation (20 papers), HIV Research and Treatment (13 papers) and HIV/AIDS drug development and treatment (13 papers). David A. Margolis is often cited by papers focused on Hematopoietic Stem Cell Transplantation (20 papers), HIV Research and Treatment (13 papers) and HIV/AIDS drug development and treatment (13 papers). David A. Margolis collaborates with scholars based in United States, United Kingdom and Brazil. David A. Margolis's co-authors include William Spreen, John C. Pottage, James T. Casper, Marta Boffito, Susan L. Ford, Krischan J Hudson, Britt Stancil, Carolyn A. Keever-Taylor, Kimberly Y. Smith and Scott Turner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

David A. Margolis

50 papers receiving 1.7k citations

Peers

Countries citing papers authored by David A. Margolis

Since Specialization

Citations

This map shows the geographic impact of David A. Margolis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Margolis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Margolis more than expected).

Fields of papers citing papers by David A. Margolis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Margolis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Margolis. The network helps show where David A. Margolis may publish in the future.

Co-authorship network of co-authors of David A. Margolis

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Margolis. A scholar is included among the top collaborators of David A. Margolis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Margolis. David A. Margolis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) 2021 ·Patient ·Vasiliki Chounta, Edgar T. Overton, Anthony Mills, Susan Swindells, (unknown), Simon Vanveggel, Rodica Van Solingen‐Ristea, Yuanyuan Wang, Krischan J Hudson, Mark S. Shaefer, David A. Margolis, Kimberly Y. Smith, William Spreen	47
2	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy 2019 ·Biology of Blood and Marrow Transplantation ·Alix E. Seif, Yimei Li, Dimitri Monos, (unknown), Richard Aplenc, David M. Barrett, James T. Casper, Jason L. Freedman, Stephan A. Grupp, David A. Margolis, Timothy S. Olson, David T. Teachey, Carolyn A. Keever-Taylor, Yongping Wang, Julie‐An Talano, Nancy Bunin	4
3	Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial 2018 ·HIV Clinical Trials ·Miranda Murray, Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Alex R. Rinehart, William Spreen, David A. Margolis	54
4	Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial 2017 ·The Lancet HIV ·Martin Markowitz, Ian Frank, Robert M. Grant, Kenneth H. Mayer, Richard Elion, Deborah Goldstein, (unknown), Magdalena E. Sobieszczyk, Joel E. Gallant, Hong‐Van Tieu, Winkler G. Weinberg, David A. Margolis, Krischan J Hudson, Britt Stancil, Susan L. Ford, Parul Patel, Elizabeth Gould, Alex R. Rinehart, Kimberly Y. Smith, William Spreen	164
5	Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders 2017 ·Biology of Blood and Marrow Transplantation ·Lauri M. Burroughs, Akiko Shimamura, Julie‐An Talano, Jennifer Domm, Kelsey K. Baker, Colleen Delaney, Haydar Frangoul, David A. Margolis, K. Scott Baker, Eneida R. Nemecek, Amy E. Geddis, Brenda M. Sandmaier, H. Joachim Deeg, Rainer Storb, Ann E. Woolfrey	37
6	Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR) 2017 ·Biology of Blood and Marrow Transplantation ·Melissa Gabriel, Bronwen E. Shaw, Ruta Brazauskas, Min Chen, David A. Margolis, Henrik Sengeløv, Ann Dahlberg, Ibrahim Ahmed, David Delgado, Hillard M. Lazarus, Brenda Gibson, Kasiani C. Myers, Rammurti T. Kamble, Aly Abdel‐Mageed, Chi Kong Li, Mary E.D. Flowers, Minoo Battiwalla, Bipin N. Savani, Navneet S. Majhail, Peter J. Shaw	5
7	Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products 2015 ·Cytotherapy ·Fenlu Zhu, (unknown), Joanne Kurtzberg, Barbara Waters‐Pick, Parameswaran Hari, David A. Margolis, Carolyn A. Keever-Taylor	11
8	Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial 2015 ·The Lancet Infectious Diseases ·David A. Margolis, Cynthia Brinson, Graham Smith, Jerome De Vente, Debbie Hagins, Joseph J. Eron, Sandy Griffith, M H St Clair, Marita Stevens, Peter Williams, Susan L. Ford, Britt Stancil, (unknown), Krischan J Hudson, Kimberly Y. Smith, William Spreen	157
9	Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans 2015 ·Xenobiotica ·Gary D. Bowers, (unknown), Melinda J. Reese, (unknown), (unknown), Stephen C. Piscitelli, Phuong Tu Huynh, David S. Wagner, Susan L. Ford, Elizabeth Gould, (unknown), Yu Lou, David A. Margolis, William Spreen	46
10	Long-acting antiviral agents for HIV treatment 2015 ·Current Opinion in HIV and AIDS ·David A. Margolis, Marta Boffito	59
11	Long-acting injectable antiretrovirals for HIV treatment and prevention 2013 ·Current Opinion in HIV and AIDS ·William Spreen, David A. Margolis, John C. Pottage	206
12	Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES 2012 ·AIDS Research and Human Retroviruses ·Benjamin Young, Kathleen Squires, Lisa Ross, Lizette Santiago, Louis Sloan, Henry Zhao, (unknown), Gary E. Pakes, David A. Margolis, Mark S. Shaefer	17
13	Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children 2010 ·Biology of Blood and Marrow Transplantation ·Paul Woodard, Paul A. Carpenter, Stella M. Davies, Thomas G. Gross, Wensheng He, Mei-Jie Zhang, Biljana Horn, David A. Margolis, John P. Perentesis, Jean E. Sanders, Kirk R. Schultz, Adriana Seber, William G. Woods, Mary Eapen	16
14	Intertriginous Eruption Associated With Chemotherapy in Pediatric Patients 2007 ·Archives of Dermatology ·(unknown), (unknown), Kristen E. Holland, David A. Margolis, Beth A. Drolet	13
15	Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL 2005 ·Bone Marrow Transplantation ·Julie‐An Talano, James T. Casper, Bruce M. Camitta, Carolyn A. Keever-Taylor, K Murray, Mary Eapen, Karen Pierce, David A. Margolis	9
16	Malignant infantile osteopetrosis & primary pulmonary hypertension: A new combination? 2003 ·Pediatric Blood & Cancer ·Kimberly A. Kasow, Carmem Bonfim, Julie Asch, David A. Margolis, Jesse Jenkins, Robert F. Tamburro, Rupert Handgretinger, Edwin M. Horwitz	11
17	In vitro T‐cell receptor Vβ repertoire analysis may identify which T‐cell Vβ families mediate graft‐versus‐leukaemia and graft‐versus‐host responses after human leucocyte antigen‐matched sibling stem cell transplantation 2001 ·British Journal of Haematology ·Diane E. Epperson, David A. Margolis, Laura McOlash, (unknown), A. John Barrett	19
18	Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion 2001 ·Biology of Blood and Marrow Transplantation ·Carolyn A. Keever-Taylor, Christopher Bredeson, Fausto R. Loberiza, James T. Casper, C.A. Lawton, Douglas Rizzo, William H. Burns, David A. Margolis, David H. Vesole, Mary Horowitz, Mei-Jie Zhang, Mark Juckett, William R. Drobyski	51
19	Infiltrating T cells during liver graft-versus-host disease show a restricted T-cell repertoire 2000 ·Biology of Blood and Marrow Transplantation ·David A. Margolis, J. Casper, Annette D. Segura, (unknown), Laura McOlash, Barbra M. Fisher, Kristin S. Miller, Jack Gorski	20
20	Hematopoietic stem cell transplantation for severe aplastic anemia 1998 ·Current Opinion in Hematology ·David A. Margolis, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact